THOMAS WESTBROOK to Xenograft Model Antitumor Assays
This is a "connection" page, showing publications THOMAS WESTBROOK has written about Xenograft Model Antitumor Assays.
Connection Strength
0.362
-
Combinatorial inhibition of PTPN12-regulated receptors leads to a broadly effective therapeutic strategy in triple-negative breast cancer. Nat Med. 2018 05; 24(4):505-511.
Score: 0.114
-
Selective small molecule Stat3 inhibitor reduces breast cancer tumor-initiating cells and improves recurrence free survival in a human-xenograft model. PLoS One. 2012; 7(8):e30207.
Score: 0.077
-
Inhibition of YTHDF2 triggers proteotoxic cell death in MYC-driven breast cancer. Mol Cell. 2021 08 05; 81(15):3048-3064.e9.
Score: 0.036
-
Metabolic enzyme PFKFB4 activates transcriptional coactivator SRC-3 to drive breast cancer. Nature. 2018 04; 556(7700):249-254.
Score: 0.029
-
The spliceosome is a therapeutic vulnerability in MYC-driven cancer. Nature. 2015 Sep 17; 525(7569):384-8.
Score: 0.024
-
Elevated CDCP1 predicts poor patient outcome and mediates ovarian clear cell carcinoma by promoting tumor spheroid formation, cell migration and chemoresistance. Oncogene. 2016 Jan 28; 35(4):468-78.
Score: 0.023
-
Overcoming endocrine resistance due to reduced PTEN levels in estrogen receptor-positive breast cancer by co-targeting mammalian target of rapamycin, protein kinase B, or mitogen-activated protein kinase kinase. Breast Cancer Res. 2014 Sep 11; 16(5):430.
Score: 0.022
-
A role for PVRL4-driven cell-cell interactions in tumorigenesis. Elife. 2013 Apr 30; 2:e00358.
Score: 0.020
-
The pINDUCER lentiviral toolkit for inducible RNA interference in vitro and in vivo. Proc Natl Acad Sci U S A. 2011 Mar 01; 108(9):3665-70.
Score: 0.017